Investigators say that they do not have any safety concerns regarding GEN-001 and avelumab in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric Cancer
Latest News
Advertisement
Advertisement
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
ByDaniel V. T. Catenacci, MD,Yoon-Koo Kang, MD, PhD,Hope E. Uronis, MD, MHS,Keun-Wook Lee, MD, PhD,Matthew C. H. Ng, MD,Peter C. Enzinger, MD,Se Hoon Park, MD, PhD,Philip J. Gold, MD,Jill Lacy, MD,Howard S. Hochster, MD,Sang Cheul Oh, MD, PhD,Yeul Hong Kim, MD, PhD,Kristen A. Marrone, MD,Ronan J. Kelly, MD,Rosalyn A. Juergens, MD,Jong Gwang Kim, MD, PhD,Thierry Alcindor, MD, MSc,Sun Jin Sym, MD, PhD,Eun-Kee Song, MD, PhD,Cheng Ean Chee, MD,Yee Chao, MD, PhD,Sunnie Kim, MD,Do-Youn Oh, MD, PhD,Jennifer Yen, PhD,Justin I. Odegaard, MD, PhD,Errin Lagow, PhD,Daner Li, MS,Jichao Sun, PhD,Patrick Kaminker, PhD,Paul A. Moore, PhD,Minori Koshiji Rosales, MD, PhD,Haeseong Park, MD, MPH
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma may experience significant survival benefit following treatment with zolbetuximab.
The safety profile of tislelizumab plus chemotherapy in the phase 3 RATIONALE 305 trial appears to be manageable in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
The FDA sets a Prescription Drug User Fee Act date of December 16, 2023 for pembrolizumab plus chemotherapy for managing metastatic gastric or gastroesophageal junction adenocarcinoma.
Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College
Patients from China with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma can now be treated with tislelizumab plus chemotherapy following its approval.
Phase 3 KEYNOTE-859 trial data favor pembrolizumab plus chemotherapy over chemotherapy alone in the frontline setting for metastatic or unresectable gastric or gastroesophageal junction cancer.
Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.
HER-Vaxx with standard-of-care chemotherapy yielded benefit in patients with HER2-overexpressing metastatic or advanced gastric/gastroesophaeal junction adenocarcinoma.
Pre-operative tremelimumab plus durvalumab elicited encouraging safety and activity in patients with microsatellite instability–high resectable gastric or gastroesophageal junction cancer.
The findings, according to a group of researchers, warrant the development of treatments that attack HER2-low advanced gastric cancer.
Topline results from the phase 3 GLOW trial indicated that zolbetuximab plus CAPOX yielded a statistically significant increase in progression-free survival over placebo/CAPOX.
Patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in the European Union can now receive treatment with fam-trastuzumab deruxtecan-nxki following its approval.
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Pembrolizumab plus chemotherapy yielded a significant improvement in overall survival compared with placebo plus chemotherapy in patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Zolbetuximab Reaches PFS End Point in CLDN18.2+ HER2– Advanced/Metastatic Gastric/GEJ Adenocarcinoma
Zolbetuximab and mFOLFOX6 combination therapy demonstrated positive topline efficacy and safety in patients with Claudin 18.2–positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.
Data from the phase 2 FIGHT study indicated that the monoclonal antibody bemarituzumab may be a promising treatment when combined with mFOLFOX6 for patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
Individuals with nonalcoholic fatty liver disease–related hepatocellular carcinoma were found to have lower rates of surveillance vs other potential causes of disease.
Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.
Prospective data found higher rates of occult signet ring cell gastric cancer among individuals with no family history of gastric cancer but who carried CDH1 P/LP variants.
Laparoscopy compared with open gastrectomy was found to produce better overall survival outcomes at the 5-year follow-up analysis for patients with advanced gastric cancer.
An analysis presented at 2022 IGCC showed that the level of CD8 + cells in the outer margin of gastric cancer tumors was significantly associated with survival outcomes and could inform prognosis.
Men with MSI-high gastric cancer may have shorter overall survival than women, regardless of treatment modality.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview
2
FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy
3
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial
4
Toripalimab Regimen Improves EFS, MPR Rate in Stage II/III NSCLC Trial
5